Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Pioneering CAR-T | Allogene Therapeutics leads in allogeneic CAR-T therapies, aiming to revolutionize cancer treatment with off-the-shelf solutions for broader patient accessibility |
Clinical Progress | Explore ALLO-316's promising results in renal cell carcinoma and the potential of cema-cel for non-Hodgkin lymphoma, despite timeline adjustments |
Financial Health | With $335.5M cash and reduced burn rate, Allogene extends runway to 2027. Analysts project revenue generation by 2027, estimating $53.2M for that yea |
Market Outlook | Analyst price targets range from $5 to $14, reflecting optimism amid challenges. Allogene's innovative approach could disrupt the CAR-T market despite fierce competition |
Metrics to compare | ALLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALLOPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −1.3x | −0.5x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | 0.9x | 2.8x | 2.6x | |
Price / LTM Sales | - | 46.1x | 3.2x | |
Upside (Analyst Target) | - | 141.6% | 40.5% | |
Fair Value Upside | Unlock | 28.7% | 4.4% | Unlock |